Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation.
INTRODUCTION
Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch® in PN. We now report our experiences with Hemopatch® in a larger and more challenging single-surgeon PN cohort.


METHODS
Our study included 45 patients who underwent PN due to suspicious renal lesions between December 2013 and March 2018. All surgeries were performed by a single surgeon using the HA Hemopatch®. Preoperative, intraoperative, and postoperative parameters were assessed.


RESULTS
Preoperative median tumor diameter was 27 mm. Median PADUA and RENAL nephrometry scores were 7 and 6, respectively. In 13.3% of the cases an additional HA was applied. Intraoperative and postoperative bleeding occurred in 2.2% and 8.9%, respectively. Median total blood loss was 200 ml. Urgent pedicle clamping due to bleeding was necessary in 2 (4.4%) patients. The transfusion rate was 8.9%. There were no conversions.


CONCLUSION
We confirmed our initial results demonstrating feasibility and reliability of Hemopatch® during PN. Notably, the cohort consists of selected patients. Prospective randomized studies are needed for comparison of different types of HA with regard to perioperative outcome.
['Hupe|Marie C|MC|', 'Büttner|Maximilian|M|', 'Tabrizi|Pouriya Faraj|PF|', 'Merseburger|Axel S|AS|', 'Kuczyk|Markus A|MA|', 'Imkamp|Florian|F|http://orcid.org/0000-0003-4885-1413']
D006490:Hemostatics D006801:Humans D007680:Kidney Neoplasms D009392:Nephrectomy D023303:Oxazolidinones D011183:Postoperative Complications D011446:Prospective Studies D015203:Reproducibility of Results D012189:Retrospective Studies D066231:Surgeons D016896:Treatment Outcome
Hemopatch Hemostatic agent Partial nephrectomy Clavien–Dindo NSS Nephrology